MXCT Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£3.55 |
| 52 Week High | UK£5.55 |
| 52 Week Low | UK£3.17 |
| Beta | 1.16 |
| 11 Month Change | -7.07% |
| 3 Month Change | -18.39% |
| 1 Year Change | -24.15% |
| 33 Year Change | -63.51% |
| 5 Year Change | n/a |
| Change since IPO | 117.79% |
Recent News & Updates
Shareholder Returns
| MXCT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 3.8% | 2.8% | 2.2% |
| 1Y | -24.1% | 2.9% | 31.7% |
Return vs Industry: MXCT underperformed the US Life Sciences industry which returned 3.1% over the past year.
Return vs Market: MXCT underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| MXCT volatility | |
|---|---|
| MXCT Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MXCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MXCT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MXCT fundamental statistics | |
|---|---|
| Market cap | US$358.20m |
| Earnings (TTM) | -US$35.74m |
| Revenue (TTM) | US$45.60m |
7.9x
P/S Ratio-10.0x
P/E RatioIs MXCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MXCT income statement (TTM) | |
|---|---|
| Revenue | US$45.60m |
| Cost of Revenue | US$6.39m |
| Gross Profit | US$39.21m |
| Other Expenses | US$74.94m |
| Earnings | -US$35.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 85.98% |
| Net Profit Margin | -78.37% |
| Debt/Equity Ratio | 0% |
How did MXCT perform over the long term?
See historical performance and comparison